TAK-931

DRUG2 trials

Sponsors

Millennium Pharmaceuticals, Inc.

Conditions

Carcinoma, Non-small-cell LungColorectal CancerEsophageal NeoplasmsMetastatic Pancreatic CancerNonhematologic Neoplasms, Advanced

Phase 1

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

CompletedNCT02699749

Millennium Pharmaceuticals, Inc.Nonhematologic Neoplasms, Advanced

Start: 2016-03-24End: 2019-12-21Updated: 2021-02-21

Phase 2

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

CompletedNCT03261947

Millennium Pharmaceuticals, Inc.Carcinoma, Non-small-cell Lung, Colorectal Cancer, Esophageal Neoplasms +1

Start: 2017-10-25End: 2020-08-24Updated: 2021-09-20

Related Papers

A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.

2022-11-212 citations

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Cancer Research Communications2022-10-2712 citations

First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2018-05-2011 citations